INVA (Innoviva, Inc.) Stock Financials & Earnings | Market Cap Arena

INVA (Innoviva, Inc.) Stock Financials & Earnings | Market Cap Arena

INVAInnoviva, Inc.

Mkt Cap$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$415M

Net Income (TTM)$271M

EPS (TTM)$3.05

Free Cash Flow (TTM)$195M

Gross Margin78.9%

Op. Margin-4.0%

Net Margin65.4%

FCF Margin46.9%

P/S Ratio (TTM)3.5x

P/E Ratio (TTM)5.4x

YoY Rev Growth+14.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$76M	$53M	$21M
Q2 23	$81M	$57M	$18M
Q3 23	$67M	$57M	$24M
Q4 23	$86M	$73M	$38M
Q1 24	$77M	$67M	$26M
Q2 24	$103M	$85M	$55M
Q3 24	$90M	$80M	$50M
Q4 24	$92M	$85M	$43M
Q1 25	$89M	$80M	-$41M
Q2 25	$100M	$90M	-$49M
Q3 25	$108M	$82M	$35M
Q4 25	$118M	$76M	$39M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	4.6x	6.2x
Q2 23	5.0x	6.2x
Q3 23	5.0x	29.1x
Q4 23	4.7x	8.1x
Q1 24	4.7x	8.0x
Q2 24	4.3x	10.0x
Q3 24	4.1x	22.5x
Q4 24	4.0x	62.1x
Q1 25	3.9x	—
Q2 25	3.9x	37.6x
Q3 25	3.7x	11.4x
Q4 25	3.5x	5.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$26M	$26M
Q2 23	$38M	$38M
Q3 23	$44M	$44M
Q4 23	$33M	$33M
Q1 24	$37M	$37M
Q2 24	$44M	$44M
Q3 24	$49M	$48M
Q4 24	$59M	$55M
Q1 25	$49M	$49M
Q2 25	$44M	$44M
Q3 25	$50M	$49M
Q4 25	$55M	$53M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$33K
Q2 23	$0
Q3 23	$227K
Q4 23	$151K
Q1 24	$0
Q2 24	$0
Q3 24	$270K
Q4 24	$4M
Q1 25	$0
Q2 25	$0
Q3 25	$1M
Q4 25	$1M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-15.2%	+348.2%
Q2 23	-25.2%	+143.5%
Q3 23	+0.0%	-21.8%
Q4 23	+30.4%	+38.2%
Q1 24	+1.5%	-6.5%
Q2 24	+27.6%	-22.1%
Q3 24	+33.1%	-7.4%
Q4 24	+7.0%	+0.7%
Q1 25	+14.4%	+151.6%
Q2 25	-3.0%	+206.2%
Q3 25	+20.4%	+84.2%
Q4 25	+28.6%	+62.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$2M	2.1%
Q2 23	$2M	1.9%
Q3 23	$1M	2.1%
Q4 23	$1M	1.5%
Q1 24	$1M	1.9%
Q2 24	$2M	1.6%
Q3 24	$2M	1.8%
Q4 24	$2M	1.8%
Q1 25	$2M	2.4%
Q2 25	$2M	2.4%
Q3 25	$0	0.0%
Q4 25	$16M	13.7%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$13M	—
Q2 23	$15M	—
Q3 23	$4M	—
Q4 23	$2M	$26M
Q1 24	$4M	$30M
Q2 24	$3M	$28M
Q3 24	$4M	$26M
Q4 24	$4M	$31M
Q1 25	$4M	$27M
Q2 25	$8M	$26M
Q3 25	$14M	$27M
Q4 25	$5M	$32M

Revenue Segments

Quarter	License	License Revenue	Product	Royalty	License And Other Revenue
Q1 23	$2M	$8M	$12M	$57M	—
Q2 23	—	$3M	$16M	$62M	—
Q3 23	—	—	$14M	$54M	—
Q4 23	—	—	$20M	$66M	—
Q1 24	—	—	$19M	$58M	—
Q2 24	—	$15M	$22M	$64M	—
Q3 24	—	$5M	$28M	$57M	—
Q4 24	—	—	$29M	$63M	—
Q1 25	—	—	$30M	$58M	$546K
Q2 25	—	—	$35M	$64M	$910K
Q3 25	—	—	$47M	$60M	$610K
Q4 25	—	—	$59M	$55M	$653K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$144M	$0	$144M
Q2 23	$173M	$0	$173M
Q3 23	$180M	$0	$180M
Q4 23	$194M	$0	$194M
Q1 24	$178M	$0	$178M
Q2 24	$217M	$0	$217M
Q3 24	$261M	$0	$261M
Q4 24	$305M	$108M	$412M
Q1 25	$319M	$128M	$447M
Q2 25	$398M	$100M	$498M
Q3 25	$477M	$57M	$533M
Q4 25	$551M	$0	$551M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	90M	+28.9%
Q2 23	65M	-27.1%
Q3 23	86M	+31.6%
Q4 23	85M	-1.4%
Q1 24	85M	-0.5%
Q2 24	63M	-26.0%
Q3 24	63M	+0.7%
Q4 24	84M	+33.8%
Q1 25	63M	-25.5%
Q2 25	84M	+34.7%
Q3 25	85M	+0.6%
Q4 25	85M	+0.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$843K	10
FY 15	$4M	13
FY 16	$10M	14
FY 17	$18M	12
FY 18	$44M	6
FY 19	$44M	6
FY 20	$67M	5
FY 21	$78M	5
FY 22	$66M	5
FY 23	$3M	112
FY 24	$3M	127
FY 25	$425	1.0M